Ladenburg analyst Matthew Kaplan raised the firm’s price target on Corcept Therapeutics to $61 from $50 and keeps a Buy rating on the shares. Corcept reported preliminary 4Q23 revenue of $135.4M versus the firm’s expectation of $127.8M and is investing in improving the screening and treatment of patients to improve revenue growth, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics announces $200M stock buyback
- Corcept Therapeutics guides FY24 revenue at $600M-$630M, consensus $513.9M
- Corcept Therapeutics sees Q4 revenue at $135.4M, consnesus $127.9M
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics price target lowered to $28 from $34 at H.C. Wainwright
